GlyCardial completes patient enrolment in the EDICA trial to validate its novel diagnostic device for myocardial ischemia
GlyCardial Diagnostics, based in the Barcelona Science Park, announces the completion of the recruitment in the EDICA trial, a multicenter international in vitro study –which will involve ten hospitals from in Spain and United Kingdom (UK)– designed to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of myocardial ischaemia.
The study has been conducted in 10 sites in UK and Spain: Lister Hospital – East and North Hertfordshire NHS Trust, West Middlesex University Hospital, Hospital Universitario La Paz, Hospital de la Santa Creu i Sant Pau, Hospital Universitario Central de Asturias, Hospital Clínico Universitario de Santiago, Hospital Álvaro Cunqueiro, Hospital Universitario San Juan de Alicante , Hospital General Universitario Gregorio Marañón i Hospital Universitario Virgen Macarena.
This is a key milestone for the company that has been possible due to the commitment and hard work of all the sites, and even more in the context of the COVID-19 pandemic.
The EDICA trial it is designed to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of myocardial ischaemia, and is part of the AGLYC Project, funded by the European Commission under the Horizon 2020 Framework Programme SME Instrument.
The validation of this novel biomarker will be an important breakthrough in the cardiovascular field, as currently there are no specific biomarkers for the early detection of ischemia. This early diagnosis will allow to identify the event when the cardiac damage is still reversible, minimizing the consequences of the disease.